Geode Capital Management LLC Sells 2,161 Shares of Korro Bio, Inc. (NASDAQ:KRRO)

Geode Capital Management LLC lessened its holdings in shares of Korro Bio, Inc. (NASDAQ:KRRO) by 1.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 137,497 shares of the company’s stock after selling 2,161 shares during the quarter. Geode Capital Management LLC owned about 1.47% of Korro Bio worth $4,596,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Atlas Venture Life Science Advisors LLC raised its stake in Korro Bio by 1.6% in the second quarter. Atlas Venture Life Science Advisors LLC now owns 1,137,149 shares of the company’s stock valued at $38,515,000 after purchasing an additional 17,857 shares in the last quarter. NEA Management Company LLC raised its position in shares of Korro Bio by 1.7% during the 2nd quarter. NEA Management Company LLC now owns 1,090,793 shares of the company’s stock valued at $36,945,000 after buying an additional 17,857 shares in the last quarter. Point72 Asset Management L.P. raised its position in shares of Korro Bio by 71.6% during the 2nd quarter. Point72 Asset Management L.P. now owns 456,085 shares of the company’s stock valued at $15,448,000 after buying an additional 190,259 shares in the last quarter. State Street Corp lifted its holdings in shares of Korro Bio by 18.9% during the 3rd quarter. State Street Corp now owns 118,765 shares of the company’s stock worth $3,969,000 after acquiring an additional 18,877 shares during the last quarter. Finally, Driehaus Capital Management LLC purchased a new position in Korro Bio in the second quarter worth $3,958,000. Hedge funds and other institutional investors own 13.18% of the company’s stock.

Analysts Set New Price Targets

KRRO has been the topic of a number of research reports. Raymond James initiated coverage on Korro Bio in a research report on Monday, October 21st. They set a “strong-buy” rating and a $153.00 price target on the stock. HC Wainwright restated a “buy” rating and issued a $115.00 target price on shares of Korro Bio in a research report on Friday, November 22nd. Royal Bank of Canada increased their price target on shares of Korro Bio from $95.00 to $105.00 and gave the company an “outperform” rating in a research report on Monday, October 21st. Finally, William Blair restated an “outperform” rating on shares of Korro Bio in a report on Wednesday, November 13th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $142.17.

Korro Bio Stock Up 4.4 %

Shares of Korro Bio stock opened at $42.84 on Monday. Korro Bio, Inc. has a one year low of $30.00 and a one year high of $98.00. The business’s 50 day simple moving average is $50.61 and its two-hundred day simple moving average is $45.98.

Korro Bio (NASDAQ:KRRO) last issued its earnings results on Tuesday, November 12th. The company reported ($2.26) EPS for the quarter, topping the consensus estimate of ($2.55) by $0.29. On average, research analysts predict that Korro Bio, Inc. will post -9.63 EPS for the current fiscal year.

Insider Buying and Selling at Korro Bio

In related news, CFO Vineet Agarwal sold 800 shares of the firm’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $70.00, for a total value of $56,000.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 5.40% of the company’s stock.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).